<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00897104</url>
  </required_header>
  <id_info>
    <org_study_id>0462-029</org_study_id>
    <secondary_id>2009_593</secondary_id>
    <nct_id>NCT00897104</nct_id>
  </id_info>
  <brief_title>MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Parallel-Groups, Outpatient Study to Compare the Efficacy and Safety of MK0462 5 mg p.o. and Sumatriptan 50 mg p.o. for the Acute Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      A study to compare rizatriptan (MK0462) 5 mg by mouth (p.o.) and sumatriptan 50 mg p.o. for
      the acute treatment of a migraine attack.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 1995</start_date>
  <completion_date type="Actual">September 1996</completion_date>
  <primary_completion_date type="Actual">May 1996</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Relief at 2 Hours After Treatment</measure>
    <time_frame>2 hours after treatment</time_frame>
    <description>Participants reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe pain) at baseline to grades 0 or 1 (no headache or mild pain) at 2 hours after treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Relief Within 2 Hours After Treatment</measure>
    <time_frame>within 2 hours after treatment</time_frame>
    <description>Participants reporting time to relief (defined as the first time that a participant reported grade 0 or 1 in headache severity within 2 hours after treatment (for the comparison of rizatriptan 5 mg and sumatriptan 50 mg).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Free at 2 Hours After Treatment</measure>
    <time_frame>2 hours after treatment</time_frame>
    <description>Participants pain free (defined as a reduction of headache severity to grade 0 [no pain]) at 2 hours after treatment. Each participant rated headache severity on a 4-grade scale (0 = no headache; 1 = mild pain; 2 = moderate pain; 3 = severe pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lack of Functional Disability at 2 Hours After Treatment as Measured by the Level of Impairment in Daily Activities</measure>
    <time_frame>2 hours after treatment</time_frame>
    <description>Participants with no functional disability measured by the level of impairment to daily activities at 2 hours after treatment. Each participant rated functional disability on a 4-grade scale (0 =normal; 1 = daily activities mildly impaired; 2 = daily activities severely impaired; 3 =unable to carry out daily activities, required bed rest).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or Absence of Associated Symptoms (Photophobia, Phonophobia, Nausea, and Vomiting) at 2 Hours After Treatment</measure>
    <time_frame>2 hours after treatment</time_frame>
    <description>Participants who recorded the presence or absence of the associated symptoms photophobia, phonophobia, nausea, and vomiting at 2 hours after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Who Used Escape Medication 2 Hours After the Treatment Dose</measure>
    <time_frame>2 hours after treatment</time_frame>
    <description>Escape medication is defined as rescue medication for participants who experienced lack of efficacy from the study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Relief (Time to Recurrence From the Time of First Recorded Pain Relief [Grade = 0 or 1])</measure>
    <time_frame>24 hours</time_frame>
    <description>Duration of relief or the time to recurrence from the time of first recorded pain relief (grade = 0 or 1) was calculated for responders who had a headache recurrence</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">933</enrollment>
  <condition>Migraine Headache</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rizatriptan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sumatriptan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rizatriptan benzoate (MK0462)</intervention_name>
    <description>single dose 5 mg rizatriptan p.o.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>MK0462</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: sumatriptan</intervention_name>
    <description>single dose 50 mg sumatriptan p.o.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>Placebo to rizatriptan or sumatriptan, single dose placebo tablet taken orally</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant had at least a 6-month history of migraine, with or without aura

          -  Participant was male, or if female, must have been postmenopausal, surgically
             sterilized, or taking adequate contraceptive precautions

          -  Participant was judged to be in good health, apart from migraine

        Exclusion Criteria:

          -  Participant was Pregnant or a nursing mother

          -  Participant had a history or current evidence of drug or alcohol abuse

          -  Participant had a history or clinical evidence of cardiovascular disease

          -  Participant had a clinically significant Electrocardiography (ECG) abnormality

          -  Participant had a resting systolic blood pressure of greater than 145 mm Hg or
             diastolic of less than 95 mm Hg at screening

          -  Participant had received treatment with an investigational device or compound within
             30 days of the study

          -  Participant typically suffered from less then 1 or more than 8 attacks of migraine per
             month

          -  Participant had difficulty in distinguishing his/her migraine attacks from tension or
             interval headaches

          -  Participant was currently taking monoamine oxidase inhibitors, methysergide or lithium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <reference>
    <citation>Ho TW, Fan X, Rodgers A, Lines CR, Winner P, Shapiro RE. Age effects on placebo response rates in clinical trials of acute agents for migraine: pooled analysis of rizatriptan trials in adults. Cephalalgia. 2009 Jul;29(7):711-8. doi: 10.1111/j.1468-2982.2008.01788.x. Epub 2009 Feb 3.</citation>
    <PMID>19210513</PMID>
  </reference>
  <results_reference>
    <citation>Ferrari MD, Loder E, McCarroll KA, Lines CR. Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials. Cephalalgia. 2001 Mar;21(2):129-36.</citation>
    <PMID>11422095</PMID>
  </results_reference>
  <results_reference>
    <citation>Block GA, Goldstein J, Polis A, Reines SA, Smith ME. Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Rizatriptan Multicenter Study Groups. Headache. 1998 Nov-Dec;38(10):764-71.</citation>
    <PMID>11284464</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2009</study_first_submitted>
  <study_first_submitted_qc>May 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <results_first_submitted>September 26, 2009</results_first_submitted>
  <results_first_submitted_qc>June 22, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 23, 2010</results_first_posted>
  <last_update_submitted>February 13, 2015</last_update_submitted>
  <last_update_submitted_qc>February 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sumatriptan</mesh_term>
    <mesh_term>Rizatriptan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at 31 sites: 6 in UK, 9 in Norway, 2 in Switzerland, and 14 in Sweden
First Participant Treated: August 1995
Last Participant Treated: May 1996.</recruitment_details>
      <pre_assignment_details>Participants screened at a pretreatment visit were given allocated drug supply with instructions. If participants had not treated an attack within 2 months of being enrolled, they were required to return for a rescreen visit. If by 4 months after being enrolled participants still had not treated an attack, they were discontinued from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rizatriptan 5 mg</title>
          <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
        </group>
        <group group_id="P2">
          <title>Sumatriptan 5 mg</title>
          <description>Sumatriptan 5 mg orally once for treatment of single migraine attack</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo matching Rizatriptan 5 mg or Sumatriptan 5 mg orally once for treatment of single migraine attack</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="418">Participants who were allocated study drug</participants>
                <participants group_id="P2" count="428">Participants who were allocated study drug</participants>
                <participants group_id="P3" count="87">Participants who were allocated study drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Treated</title>
              <participants_list>
                <participants group_id="P1" count="355">Participants who took study drug</participants>
                <participants group_id="P2" count="357">Participants who took study drug</participants>
                <participants group_id="P3" count="80">Participants who took study drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="63">Participants who did not take study drug</participants>
                <participants group_id="P2" count="71">Participants who did not take study drug</participants>
                <participants group_id="P3" count="7">Participants who did not take study drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="354">Participants who took study drug and completed the study</participants>
                <participants group_id="P2" count="357">Participants who took study drug and completed the study</participants>
                <participants group_id="P3" count="79">Participants who took study drug and completed the study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="71"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Prestudy Labs</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Baseline ECG</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Need for Concom. Med.</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Migraine Attack</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Longer Met Inc/Exc Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rizatriptan 5 mg</title>
          <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
        </group>
        <group group_id="B2">
          <title>Sumatriptan 5 mg</title>
          <description>Sumatriptan 5 mg orally once for treatment of single migraine attack</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo matching Rizatriptan 5 mg or Sumatriptan 5 mg orally once for treatment of single migraine attack</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="355"/>
            <count group_id="B2" value="357"/>
            <count group_id="B3" value="80"/>
            <count group_id="B4" value="792"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.9" spread="10.3"/>
                    <measurement group_id="B2" value="41.8" spread="10.1"/>
                    <measurement group_id="B3" value="44.3" spread="10.5"/>
                    <measurement group_id="B4" value="41.2" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="291"/>
                    <measurement group_id="B2" value="291"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="352"/>
                    <measurement group_id="B2" value="356"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Headache Severity</title>
          <description>Each participant rated headache severity on a 4-grade scale (0 = no headache; 1 = mild pain; 2 = moderate pain; 3 = severe pain).</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Grades 0,1: no pain, Mild, or missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="216"/>
                    <measurement group_id="B2" value="221"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Relief at 2 Hours After Treatment</title>
        <description>Participants reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe pain) at baseline to grades 0 or 1 (no headache or mild pain) at 2 hours after treatment</description>
        <time_frame>2 hours after treatment</time_frame>
        <population>An “all-participants-treated” approach was used in the primary analysis, including all participants who had at least one assessment of pain severity within 2 hours after dose. Missing data were replaced by carrying forward the preceding value.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan 5 mg</title>
            <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Sumatriptan 5 mg</title>
            <description>Sumatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching Rizatriptan 5 mg or Sumatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief at 2 Hours After Treatment</title>
          <description>Participants reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe pain) at baseline to grades 0 or 1 (no headache or mild pain) at 2 hours after treatment</description>
          <population>An “all-participants-treated” approach was used in the primary analysis, including all participants who had at least one assessment of pain severity within 2 hours after dose. Missing data were replaced by carrying forward the preceding value.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="352"/>
                <count group_id="O2" value="356"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2-hour pain relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223"/>
                    <measurement group_id="O2" value="238"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No 2-hour pain relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="118"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Relief Within 2 Hours After Treatment</title>
        <description>Participants reporting time to relief (defined as the first time that a participant reported grade 0 or 1 in headache severity within 2 hours after treatment (for the comparison of rizatriptan 5 mg and sumatriptan 50 mg).</description>
        <time_frame>within 2 hours after treatment</time_frame>
        <population>An “all-participants-treated” approach was used in the primary analysis, including all participants who had at least one assessment of pain severity within 2 hours after test medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan 5 mg</title>
            <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Sumatriptan 5 mg</title>
            <description>Sumatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching Rizatriptan 5 mg or Sumatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Relief Within 2 Hours After Treatment</title>
          <description>Participants reporting time to relief (defined as the first time that a participant reported grade 0 or 1 in headache severity within 2 hours after treatment (for the comparison of rizatriptan 5 mg and sumatriptan 50 mg).</description>
          <population>An “all-participants-treated” approach was used in the primary analysis, including all participants who had at least one assessment of pain severity within 2 hours after test medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="352"/>
                <count group_id="O2" value="356"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First pain relief within 2 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="247"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain relief did not occur within 2 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="109"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Free at 2 Hours After Treatment</title>
        <description>Participants pain free (defined as a reduction of headache severity to grade 0 [no pain]) at 2 hours after treatment. Each participant rated headache severity on a 4-grade scale (0 = no headache; 1 = mild pain; 2 = moderate pain; 3 = severe pain).</description>
        <time_frame>2 hours after treatment</time_frame>
        <population>An “all-participants-treated” approach was used in the secondary analysis, including all participants who had at least one assessment of pain severity within 2 hours after test medication. Missing data were replaced by carrying forward the preceding value.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan 5 mg</title>
            <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Sumatriptan 5 mg</title>
            <description>Sumatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching Rizatriptan 5 mg or Sumatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Free at 2 Hours After Treatment</title>
          <description>Participants pain free (defined as a reduction of headache severity to grade 0 [no pain]) at 2 hours after treatment. Each participant rated headache severity on a 4-grade scale (0 = no headache; 1 = mild pain; 2 = moderate pain; 3 = severe pain).</description>
          <population>An “all-participants-treated” approach was used in the secondary analysis, including all participants who had at least one assessment of pain severity within 2 hours after test medication. Missing data were replaced by carrying forward the preceding value.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="352"/>
                <count group_id="O2" value="356"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2-hour pain freedom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="113"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No 2-hour pain freedom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257"/>
                    <measurement group_id="O2" value="243"/>
                    <measurement group_id="O3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lack of Functional Disability at 2 Hours After Treatment as Measured by the Level of Impairment in Daily Activities</title>
        <description>Participants with no functional disability measured by the level of impairment to daily activities at 2 hours after treatment. Each participant rated functional disability on a 4-grade scale (0 =normal; 1 = daily activities mildly impaired; 2 = daily activities severely impaired; 3 =unable to carry out daily activities, required bed rest).</description>
        <time_frame>2 hours after treatment</time_frame>
        <population>An “all-participants-treated” approach was used in the secondary analysis. Missing data were replaced by carrying forward the preceding value.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan 5 mg</title>
            <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Sumatriptan 5 mg</title>
            <description>Sumatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching Rizatriptan 5 mg or Sumatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Lack of Functional Disability at 2 Hours After Treatment as Measured by the Level of Impairment in Daily Activities</title>
          <description>Participants with no functional disability measured by the level of impairment to daily activities at 2 hours after treatment. Each participant rated functional disability on a 4-grade scale (0 =normal; 1 = daily activities mildly impaired; 2 = daily activities severely impaired; 3 =unable to carry out daily activities, required bed rest).</description>
          <population>An “all-participants-treated” approach was used in the secondary analysis. Missing data were replaced by carrying forward the preceding value.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="350"/>
                <count group_id="O2" value="355"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="116"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mildly Impaired</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="148"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severely Impaired</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Required Bed Rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence or Absence of Associated Symptoms (Photophobia, Phonophobia, Nausea, and Vomiting) at 2 Hours After Treatment</title>
        <description>Participants who recorded the presence or absence of the associated symptoms photophobia, phonophobia, nausea, and vomiting at 2 hours after treatment.</description>
        <time_frame>2 hours after treatment</time_frame>
        <population>“All-participants-treated” approach was used. Missing data were replaced by carrying forward the preceding value. Participants Analyzed For Nausea: Rizatriptan 348; Sumatriptan 352; Placebo 78. Participants Analyzed for Vomiting: Rizatriptan 342; Sumatriptan 342; Placebo 73. Number of participants analyzed is correct for the other categories.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan 5 mg</title>
            <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Sumatriptan 5 mg</title>
            <description>Sumatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching Rizatriptan 5 mg or Sumatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Presence or Absence of Associated Symptoms (Photophobia, Phonophobia, Nausea, and Vomiting) at 2 Hours After Treatment</title>
          <description>Participants who recorded the presence or absence of the associated symptoms photophobia, phonophobia, nausea, and vomiting at 2 hours after treatment.</description>
          <population>“All-participants-treated” approach was used. Missing data were replaced by carrying forward the preceding value. Participants Analyzed For Nausea: Rizatriptan 348; Sumatriptan 352; Placebo 78. Participants Analyzed for Vomiting: Rizatriptan 342; Sumatriptan 342; Placebo 73. Number of participants analyzed is correct for the other categories.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="350"/>
                <count group_id="O2" value="354"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2-hour Photophobia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="153"/>
                    <measurement group_id="O3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No 2-hour Photophobia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189"/>
                    <measurement group_id="O2" value="201"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-hour Phonophobia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="125"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No 2-hour Phonophobia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224"/>
                    <measurement group_id="O2" value="229"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-hour Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="131"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No 2-hour Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243"/>
                    <measurement group_id="O2" value="221"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Analyzed for Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-hour Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No 2-hour Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330"/>
                    <measurement group_id="O2" value="330"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Analyzed for Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Who Used Escape Medication 2 Hours After the Treatment Dose</title>
        <description>Escape medication is defined as rescue medication for participants who experienced lack of efficacy from the study medication.</description>
        <time_frame>2 hours after treatment</time_frame>
        <population>An “all-participants-treated” approach was used in the secondary analysis. Missing data were replaced by carrying forward the preceding value.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan 5 mg</title>
            <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Sumatriptan 5 mg</title>
            <description>Sumatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching Rizatriptan 5 mg or Sumatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Used Escape Medication 2 Hours After the Treatment Dose</title>
          <description>Escape medication is defined as rescue medication for participants who experienced lack of efficacy from the study medication.</description>
          <population>An “all-participants-treated” approach was used in the secondary analysis. Missing data were replaced by carrying forward the preceding value.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="357"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Used Escape Medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not Use Escape Medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282"/>
                    <measurement group_id="O2" value="302"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Relief (Time to Recurrence From the Time of First Recorded Pain Relief [Grade = 0 or 1])</title>
        <description>Duration of relief or the time to recurrence from the time of first recorded pain relief (grade = 0 or 1) was calculated for responders who had a headache recurrence</description>
        <time_frame>24 hours</time_frame>
        <population>The duration of relief, or the time to recurrence from the time of first recorded pain relief (grade = 0 or 1), was calculated for responders who had a headache recurrence.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan 5 mg</title>
            <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Sumatriptan 5 mg</title>
            <description>Sumatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching Rizatriptan 5 mg or Sumatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Relief (Time to Recurrence From the Time of First Recorded Pain Relief [Grade = 0 or 1])</title>
          <description>Duration of relief or the time to recurrence from the time of first recorded pain relief (grade = 0 or 1) was calculated for responders who had a headache recurrence</description>
          <population>The duration of relief, or the time to recurrence from the time of first recorded pain relief (grade = 0 or 1), was calculated for responders who had a headache recurrence.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.07" spread="6.56"/>
                    <measurement group_id="O2" value="11.58" spread="5.86"/>
                    <measurement group_id="O3" value="14.38" spread="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the 24 hours treatment period, and up to and including 7 days after the last dose of study therapy.</time_frame>
      <desc>Although a participant may have had two or more adverse experiences the participant is counted only once in a category. The same participant may appear in different categories.
The At Risk population are the participants that received study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Rizatriptan 5 mg</title>
          <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
        </group>
        <group group_id="E2">
          <title>Sumatriptan 5 mg</title>
          <description>Sumatriptan 5 mg orally once for treatment of single migraine attack</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo matching Rizatriptan 5 mg or Sumatriptan 5 mg orally once for treatment of single migraine attack</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>CRISP Dictionary</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pain, Mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia/Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pain, Abdominal</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pain, Chest</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Warm Sensation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Heaviness, Regional</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pain, Back</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pain, Neck</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hypesthesia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Mental Acuity Decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Apathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Dream Abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Discomfort, Pharyngeal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No limitations were encountered in this study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

